Validation of the Beta Defensin Index (BDI) as a Biomarker for Oral Cancer in India - Hbd

Case Western Reserve university0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Consent â?? Subjects must demonstrate understanding of the study procedures as evidenced by voluntary written informed consent and has received a copy of the consent form.
•2. Compliance â?? Subjects must be willing, able, and likely to comply with all study procedures and restrictions.
•3. Age â?? Subjects must be 18 years of age or older. There are no restrictions on maximum age.
•4. Diagnosis â?? Subjects must be currently undergoing clinical evaluation for determination of OSCC diagnosis due to the presence of suspicious red or white lesions, with no prior history of HNC
•Lesions >5mm that fill the following requirements:
•i. Include non-diagnosed yet suspicious lesions of the subsites above like CIS, T1 and T2 lesions.
•ii. Include diagnosed premalignant and early malignant lesions (again CIS, T1 and T2 lesions).
•iv. Include superficial lesions like Leukoplakia, Erythroplakia and deeper but common problems.
•v. Exclude large Necrotic lesions (clinically advanced cancer T3 and T4) either diagnosed or non-diagnosed cancers in this group as often as possible

•1. Very small Lesions Less than 5 mm in size.
•2. T1, T2 Lesions with Necrotic areas.
•3. Diagnosis â?? Individuals with Prior diagnosis of any head neck malignancy.
•4. Patients with previous or current treatment involving radiation and/or chemotherapy, regardless of cancer type or cancer diagnosis dates, will be excluded.
•5. Pregnancy
•6. Anything that would place the individual at increased risk or preclude the individualâ??s full compliance with or completion of the study.

发起方